Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Advanced Carcinoid Tumors
NCT02399215Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- May 2015
- Primary completion
- Sep 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in Carcinoid Tumor (CT), sponsored by Roswell Park Comprehensive Cancer Center. Started May 2015; status: completed.
02
Drugs
nintedanib
03
Conditions
Carcinoid Tumor (CT)
Beyond the preview
Go deeper on NCT02399215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02399215.